[HTML][HTML] Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by …
T Yoshino, D Arnold, H Taniguchi, G Pentheroudakis… - Annals of …, 2018 - Elsevier
The most recent version of the European Society for Medical Oncology (ESMO) consensus
guidelines for the treatment of patients with metastatic colorectal cancer (mCRC) was …
guidelines for the treatment of patients with metastatic colorectal cancer (mCRC) was …
[HTML][HTML] Anti-EGFR and anti-VEGF agents: Important targeted therapies of colorectal liver metastases
QY Feng, Y Wei, JW Chen, WJ Chang… - World journal of …, 2014 - ncbi.nlm.nih.gov
Colorectal liver metastasis (CLM) is common worldwide. Targeted therapies with
monoclonal antibodies have been proven effective in numerous clinical trials, and are now …
monoclonal antibodies have been proven effective in numerous clinical trials, and are now …
Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer
BA Davidson, AA Secord - International journal of women's health, 2014 - Taylor & Francis
Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer. Recently, clinical
trials have focused on novel antiangiogenic agents in combination with chemotherapy or …
trials have focused on novel antiangiogenic agents in combination with chemotherapy or …
[HTML][HTML] Differences in symptom occurrence, severity, and distress ratings between patients with gastrointestinal cancers who received chemotherapy alone or …
IY Tantoy, A Dhruva, J Cataldo, A Venook… - Journal of …, 2017 - ncbi.nlm.nih.gov
Background Approximately 28% of patients with gastrointestinal (GI) cancers will receive
targeted therapy (TT) because of the associated increases in survival. Only four studies have …
targeted therapy (TT) because of the associated increases in survival. Only four studies have …
[HTML][HTML] Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis
B Rosa, JP de Jesus, EL de Mello, D Cesar… - …, 2015 - ncbi.nlm.nih.gov
Background The effectiveness of chemotherapy (CT) for select cases of metastatic colorectal
cancer (MCRC) has been well established in the literature, however, it provides limited …
cancer (MCRC) has been well established in the literature, however, it provides limited …
Target hepatic artery regional chemotherapy and bevacizumab perfusion in liver metastatic colorectal cancer after failure of first-line or second-line systemic …
H Chen, J Zhang, G Cao, P Liu, H Xu, X Wang… - Anti-Cancer …, 2016 - journals.lww.com
Colorectal cancer liver metastasis (CRLM) is a refractory disease after failure of first-line or
second-line chemotherapy. Bevacizumab is recommended as first-line therapy for advanced …
second-line chemotherapy. Bevacizumab is recommended as first-line therapy for advanced …
S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in …
Y Miyamoto, A Tsuji, H Tanioka, S Maekawa… - International journal of …, 2016 - Springer
Background Combination chemotherapy with S-1 and irinotecan is one of the standard
treatments for metastatic colorectal cancer (mCRC) in Japan. However, there are few …
treatments for metastatic colorectal cancer (mCRC) in Japan. However, there are few …
[HTML][HTML] An observational study of vascular endothelial growth factor inhibitors as second-line treatment for metastatic colorectal cancer treated with bevacizumab plus …
HL Tsai, CW Huang, CJ Ma, WC Su… - Translational Cancer …, 2019 - ncbi.nlm.nih.gov
Background The BRiTE and ARIES studies suggested that the continued use of
bevacizumab beyond progression (BBP) was beneficial. This study investigated the efficacy …
bevacizumab beyond progression (BBP) was beneficial. This study investigated the efficacy …
贝伐单抗联合化疗治疗晚期结直肠癌的近期疗效与安全性观察
郭晶晶， 郑勤 - 中国生化药物杂志, 2012 - cqvip.com
目的观察贝伐单抗联合辅助化疗治疗晚期结直肠癌的临床疗效及安全性. 方法回顾性总结2008
年1 月一2012 年6 月期间分别给予贝伐单抗联合FOLFOX4 和单独FOLFOX4 …
年1 月一2012 年6 月期间分别给予贝伐单抗联合FOLFOX4 和单独FOLFOX4 …
Angiogenesis
AA Secord, S Siamakpour-Reihani - Translational Advances in …, 2017 - Elsevier
Angiogenesis is a complex multifaceted process essential for cancer growth and
progression. The underlying biology regulating angiogenesis is incredibly complicated …
progression. The underlying biology regulating angiogenesis is incredibly complicated …